D William Cameron

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2437579/d-william-cameron-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188 8,010 85 43 h-index g-index citations papers 8,752 6.7 203 5.3 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
188	Spatiotemporal trends and socioecological factors associated with Lyme disease in eastern Ontario, Canada from 2010-2017 <i>BMC Public Health</i> , 2022 , 22, 736	4.1	O
187	Building knowledge, optimising physical and mental health and setting up healthier life trajectories in South African women (): a preconception randomised control trial part of the Healthy Life Trajectories Initiative (HeLTI) <i>BMJ Open</i> , 2022 , 12, e059914	3	1
186	Evaluation of the protein gap for detection of abnormal serum gammaglobulin level: an imperfect predictor. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 869-874	5.9	1
185	A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD. <i>International Journal of COPD</i> , 2021 , 16, 3275-3	32 8 4	1
184	Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T´cellimmune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , 2021 ,	11.7	2
183	Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations. <i>International Journal of COPD</i> , 2021 , 16, 545-552	3	1
182	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. <i>Molecular Therapy</i> , 2021 , 29, 1984-2000	11.7	13
181	Impact of in-utero antiretroviral drug exposure on expression of membrane-associated transporters in mouse placenta and fetal brain. <i>Aids</i> , 2021 , 35, 2249-2258	3.5	2
180	Intravenous immune globulin in septic shock: a Canadian national survey of critical care medicine and infectious disease specialist physicians. <i>Canadian Journal of Anaesthesia</i> , 2021 , 68, 782-790	3	1
179	Molecular Epidemiology of Mycobacterium tuberculosis To Describe the Transmission Dynamics Among Inuit Residing in Iqaluit Nunavut Using Whole-Genome Sequencing. <i>Clinical Infectious Diseases</i> , 2021 , 72, 2187-2195	11.6	4
178	The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Alternative and Complementary Medicine</i> , 2021 , 27, 225-237	2.4	12
177	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. <i>Nanomaterials</i> , 2021 , 11,	5.4	5
176	TLR-4 Agonist Induces IFN-Production Selectively in Proinflammatory Human M1 Macrophages through the PI3K-mTOR- and JNK-MAPK-Activated p70S6K Pathway. <i>Journal of Immunology</i> , 2021 , 207, 2310-2324	5.3	1
175	The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. <i>International Journal of Circumpolar Health</i> , 2020 , 79, 1758501	1.7	6
174	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. <i>BMJ Open</i> , 2020 , 10, e041359	3	
173	Beauß lines with onychomadesis in convalescence of invasive pneumococcal disease. <i>Oxford Medical Case Reports</i> , 2019 , 2019, omz098	0.6	
172	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis - Part II: Non-kidney transplant. <i>Clinical Transplantation</i> , 2019 , 33, e13625	3.8	8

171	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2019 , 33, e13560	3.8	4	
170	Bacille Calmette-Gufin Vaccine Strain Modulates the Ontogeny of Both Mycobacterial-Specific and Heterologous T Cell Immunity to Vaccination in Infants. <i>Frontiers in Immunology</i> , 2019 , 10, 2307	8.4	10	
169	A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects. <i>PLoS ONE</i> , 2019 , 14, e0223969	3.7	1	
168	Evaluation of a Personalized Subcutaneous Immunoglobulin Treatment Program for Neurological Patients. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 38-43	1	4	
167	Type of Pelvic Disease as a Risk Factor for Surgical Site Infectionin Women Undergoing Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2019 , 26, 1149-1156	2.2	3	
166	Prevalence of Hypogammaglobulinemia in Adult Invasive Pneumococcal Disease. <i>Clinical Infectious Diseases</i> , 2018 , 66, 564-569	11.6	7	
165	Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations. <i>Pilot and Feasibility Studies</i> , 2018 , 4, 135	1.9	2	
164	Chronic obstructive pulmonary disease exacerbation frequency and serum IgG levels. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 830-831	11.5	2	
163	Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. <i>Antiviral Research</i> , 2018 , 159, 45-54	10.8	6	
162	Incidence Rate of Post-Kidney Transplant Infection: A Retrospective Cohort Study Examining Infection Rates at a Large Canadian Multicenter Tertiary-Care Facility. <i>Canadian Journal of Kidney Health and Disease</i> , 2018 , 5, 2054358118799692	2.3	13	
161	Breastfeeding mitigates the effects of maternal HIV on infant infectious morbidity in the Option B+ era. <i>Aids</i> , 2018 , 32, 2383-2391	3.5	8	
160	Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. <i>Transfusion</i> , 2018 , 58, 2437-2452	2.9	8	
159	An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017 , 29, 24-31	2.2	18	
158	Barriers to and Facilitators of Adherence to Exclusive Breastfeeding Practices Among HIV Infected and Non-Infected Women in Jos, Nigeria. <i>Maternal and Child Health Journal</i> , 2017 , 21, 953-960	2.4	8	
157	A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers. <i>Transplant Infectious Disease</i> , 2017 , 19, e12706	2.7	8	
156	Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease. <i>Respiratory Medicine</i> , 2017 , 132, 181-188	4.6	29	
155	Landscape review of current HIV Rick and killPcure research - some kicking, not enough killing. <i>BMC Infectious Diseases</i> , 2017 , 17, 595	4	40	
154	A Data-Based Hypothesis Explicating Thiopurine Therapeutic Failure in Biologic-Naive UC. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 282-283	4	1	

Lymphogranuloma Venereum, Chancroid and Granuloma Inguinale **2017**, 585-591.e1

152	Increasing Number and Proportion of Adverse Obstetrical Outcomes among Women Living with HIV in the Ottawa Area: A 20-Year Clinical Case Series. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016 , 2016, 1546365	2.6	
151	Lost in translation? How adults living with Cystic Fibrosis understand treatment recommendations from their healthcare providers, and the impact on adherence to therapy. <i>Patient Education and Counseling</i> , 2016 , 99, 1319-24	3.1	7
150	A systematic review highlights a knowledge gap regarding the effectiveness of health-related training programs in journalology. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 257-65	5.7	24
149	Yet Another Flawed "Placebo Controlled" Study in CrohnB Disease?. <i>Foodborne Pathogens and Disease</i> , 2015 , 12, 812	3.8	2
148	Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015 , 4, 167	3	7
147	A Cross-Sectional Study of the Psychological Needs of Adults Living with Cystic Fibrosis. <i>PLoS ONE</i> , 2015 , 10, e0127944	3.7	4
146	A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2015 , 10, e014	123205	27
145	A statistical model to predict one-year risk of death in patients with cystic fibrosis. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 1336-45	5.7	39
144	The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada. <i>Chest</i> , 2015 , 148, 767-773	5.3	9
143	Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. <i>BMJ Open</i> , 2015 , 5, e008316	3	6
142	Assessment of stigma in patients with cystic fibrosis. BMC Pulmonary Medicine, 2014, 14, 76	3.5	12
141	Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-nalle persons with HIV. <i>PLoS ONE</i> , 2014 , 9, e85607	3.7	8
140	The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study. <i>PLoS ONE</i> , 2014 , 9, e92606	3.7	17
139	Taima (stop) TB: the impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit, Nunavut. <i>PLoS ONE</i> , 2014 , 9, e100975	3.7	19
138	The feasibility of the interferon gamma release assay and predictors of discordance with the tuberculin skin test for the diagnosis of latent tuberculosis infection in a remote Aboriginal community. <i>PLoS ONE</i> , 2014 , 9, e111986	3.7	12
137	Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1713-22	5.9	41
136	Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2014 , 39, 1183-7	3	22

(2011-2014)

135	Development and psychometric validation of a cystic fibrosis knowledge scale. <i>Respirology</i> , 2014 , 19, 1209-14	3.6	10
134	Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. <i>BMC Infectious Diseases</i> , 2014 , 14, 140	4	40
133	"Add-on" is scientifically more accurate than "placebo control" in multiple inflammatory bowel disease (IBD) trials. <i>Journal of Crohnh</i> and Colitis, 2014 , 8, 1334-5	1.5	3
132	Systematic review of the effectiveness of training programs in writing for scholarly publication, journal editing, and manuscript peer review (protocol). <i>Systematic Reviews</i> , 2013 , 2, 41	3	9
131	HIV prevention in action on the football field: the WhizzKids United program in South Africa. <i>AIDS and Behavior</i> , 2013 , 17, 2045-52	4.3	10
130	Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 382-	-91⁴	8
129	Oral immunization using HgbA in a recombinant chancroid vaccine delivered by attenuated Salmonella typhimurium SL3261 in the temperature-dependent rabbit model. <i>Journal of Immunological Methods</i> , 2012 , 375, 232-42	2.5	4
128	HIV knowledge among Canadian-born and sub-Saharan African-born patients living with HIV. <i>Journal of Immigrant and Minority Health</i> , 2012 , 14, 132-9	2.2	12
127	On the zoonosis of M. avium subspecies paratuberculosis (MAP). <i>Journal of Crohnl</i> s and Colitis, 2012 , 6, 504; author reply 505	1.5	2
126	Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. <i>PLoS ONE</i> , 2012 , 7, e36077	3.7	54
125	The effect of Etarotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. <i>Molecules</i> , 2012 , 17, 688-702	4.8	11
124	Comparison of interferon-I interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. <i>Clinical and Experimental Immunology</i> , 2012 , 167, 317-29	6.2	51
123	A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive protein. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012 , 16, 1247-51	2.1	14
122	Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. <i>Medical Decision Making</i> , 2012 , 32, 70-82	2.5	10
121	Inaccuracy of death certificate diagnosis of tuberculosis and potential underdiagnosis of TB in a region of high HIV prevalence. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 937013		9
120	Considered "negative" for MAP, these results would be very "positive" for tuberculoid leprosy. Journal of Crohnls and Colitis, 2011, 5, 373; author reply 374	1.5	
119	Use of signature-tagged mutagenesis to identify virulence determinants in Haemophilus ducreyi responsible for ulcer formation. <i>Journal of Microbiological Methods</i> , 2011 , 84, 290-8	2.8	3
118	Mouse viruses and human disease. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 264-5	25.5	2

117	Inhibition of human cytochrome p450 metabolism by blended herbal products and vitamins. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011 , 14, 1-16	3.4	9
116	Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. <i>PLoS ONE</i> , 2011 , 6, e14764	3.7	13
115	Identification and characterization of a heme periplasmic-binding protein in Haemophilus ducreyi. <i>BioMetals</i> , 2011 , 24, 709-22	3.4	2
114	Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. <i>PLoS Medicine</i> , 2011 , 8, e1001048	11.6	143
113	HIV pre-exposure prophylaxis (PrEP)a quantitative ethics appraisal. <i>PLoS ONE</i> , 2011 , 6, e22497	3.7	3
112	Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 449-54	6.2	158
111	Design and methods of the MAINTAIN study: a randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection. <i>Contemporary Clinical Trials</i> , 2010 , 31, 604-	-77	6
110	When infections collidegummatous syphilis in an HIV-infected individual. <i>International Journal of Infectious Diseases</i> , 2010 , 14 Suppl 3, e283-6	10.5	7
109	High HIV knowledge relates to low stigma in pharmacists and university health science students in Guyana, South America. <i>International Journal of Infectious Diseases</i> , 2010 , 14, e881-7	10.5	22
108	Connection domain mutations in treatment-experienced patients in the OPTIMA trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 160-6	3.1	14
107	Lymphogranuloma venereum, chancroid and granuloma inguinale 2010 , 658-664		
106	Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4840-4	5.9	5
105	Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 27-36	3.1	19
104	Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009 , 51, 631-9	3.1	37
103	Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 162-73	5.9	16
102	Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4385-92	5.9	49
101	Tuberculosis elimination in the Canadian First Nations population: assessment by a state-transfer, compartmental epidemic model. <i>International Journal of Infectious Diseases</i> , 2009 , 13, 220-6	10.5	5
100	Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis. <i>Aids</i> , 2009 , 23, 740-2	3.5	19

(2006-2008)

pain among persons living with HIV. <i>Journal of Pain and Symptom Management</i> , 2008 , 36, 247-58	4.8	38
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. <i>Journal of Clinical Virology</i> , 2008 , 41, 243-54	14.5	37
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1310-4	11.6	71
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. <i>Journal of Infectious Diseases</i> , 2008 , 198, 234-40	7	83
Proportion of HIV-1 infected CD8+CD4- T lymphocytes in vivo. <i>Current HIV Research</i> , 2008 , 6, 585-96	1.3	7
Withdrawal of Pneumocystis prophylaxis: authorsPreply. <i>Aids</i> , 2008 , 22, 324	3.5	
CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008 , 6, 4		24
The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 389-95	6.1	17
Combining social network analysis and cluster analysis to identify sexual network types. International Journal of STD and AIDS, 2007, 18, 754-9	1.4	11
Development and psychometric validation of the HIV Treatment Knowledge Scale. <i>AIDS Care -</i> Psychological and Socio-Medical Aspects of AIDS/HIV, 2007 , 19, 1141-8	2.2	38
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 957-63	5.1	11
Development and validation of the HIV Medication Readiness Scale. Assessment, 2007, 14, 408-16	3.7	34
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. <i>Annals of</i> Internal Medicine, 2007 , 146, 193-203	8	121
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count Aids, 2007 , 21, 1711-5	3.5	35
The benefits and risks of bacille Calmette-Gulin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model. <i>BMC Pediatrics</i> , 2006, 6, 5	2.6	8
Time-dependent interaction between lopinavir/ritonavir and fexofenadine. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 758-67	2.9	50
A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006 , 18, 830-8	2.2	59
Blastomycosis in a young African man presenting with a pleural effusion. <i>Canadian Respiratory</i> Journal, 2006 , 13, 441-4	2.1	7
	CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clinical Infectious Diseases, 2008, 46, 1310-4 A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. Journal of Infectious Diseases, 2008, 198, 234-40 Proportion of HIV-1 infected CD8+CD4-T lymphocytes in vivo. Current HIV Research, 2008, 6, 585-96 Withdrawal of Pneumocystis prophylaxis: authorsPreply. Aids, 2008, 22, 324 CPG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Journal of Immune Based Therapies and Vaccines, 2008, 6, 4 The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clinical Pharmacology and Therapeutics, 2007, 82, 389-95 Combining social network analysis and cluster analysis to identify sexual network types. International Journal of STD and AIDS, 2007, 18, 754-9 Development and psychometric validation of the HIV Treatment Knowledge Scale. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 1141-8 Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Journal of Antimicrobial Chemotherapy, 2007, 59, 957-63 Development and validation of the HIV Medication Readiness Scale. Assessment, 2007, 14, 408-16 Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Annals of internal Medicine, 2007, 146, 193-203 Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count Aids, 2007, 21, 1711-5 The benefits and risks of bacille Calmette-Gulin vaccination among infants at high risk for both internal Medicine, 2007, 146, 193-203 Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count Aids, 2007, 21, 17	The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. <i>Clinical Pharmacokinetics</i> of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in embination with ritonavir. <i>Clinical Infectious Diseases</i> , 2008, 41, 243-54 The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. <i>Clinical Pharmacology</i> , 1146, 193-203 Development and psychometric validation of the HIV Treatment Knowledge Scale. <i>AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 957-63 Development and validation of the HIV Medication Readiness Scale. <i>Assessment</i> , 2007, 14, 408-16 AMEA-analysis: intravenous immunoal prophylaxis is not required with a CD4+ T-cell count Aids, 2007, 21, 1711-5 The benefits and risks of bacille Calmette-Gulfin vaccination and psychological readinaries. <i>Journal of Clinical Pharmacology</i> , 2007, 59, 957-63 Development and psychometric validation of the HIV Treatment Knowledge Scale. <i>AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 1141-8 Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 957-63 Development and validation of the HIV Medication Readiness Scale. <i>Assessment</i> , 2007, 14, 408-16 Ameta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. <i>Annals of Internal Medicine</i> , 2007, 146, 193-203 Pheumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count Aids, 2007, 21, 1711-5 The benefits and risks of bacille Calmette-Gulfin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model. <i>BMC Pediatrics</i> 2.6 2006, 6, 5 Time-dependent interaction between lopinavir/ritonavir and fexofenadine. <i>Journal of Clinical Pharmacolog</i>

81	Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. <i>Aids</i> , 2006 , 20, 1941-50	3.5	34
80	Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006 , 21, 371		8
79	Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. <i>BMC Infectious Diseases</i> , 2006 , 6, 97	4	26
78	A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome. <i>European Journal of Clinical Nutrition</i> , 2006 , 60, 1266-76	5.2	43
77	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. <i>Aids</i> , 2005 , 19, 1473-9	3.5	152
76	Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. <i>Transfusion</i> , 2005 , 45, 1640-57	2.9	35
75	Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 398-404	3.8	12
74	Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits. Journal of Immunological Methods, 2005 , 299, 153-64	2.5	15
73	In vitro and in vivo activity of combination antimicrobial agents on Haemophilus ducreyi. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 552-8	5.1	4
72	Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. <i>Clinical Infectious Diseases</i> , 2005 , 41 Suppl 1, S105-9	11.6	42
71	Influenza vaccination with 1/10th the full dose. New England Journal of Medicine, 2004, 351, 2339-40	59.2	7
70	CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. <i>Journal of Clinical Immunology</i> , 2004 , 24, 693-7	′0 ⁵ 1 ⁷	284
69	The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 588-97	6.1	58
68	Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. <i>Vaccine</i> , 2004 , 22, 3136-43	4.1	199
67	Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. <i>Vaccine</i> , 2004 , 23, 615-22	4.1	91
66	Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection. <i>Aids</i> , 2004 , 18, 337-8	3.5	6
65	Use of Intravenous Immunoglobulin for Treatment of Neurological Conditions: A Systematic Review <i>Blood</i> , 2004 , 104, 3642-3642	2.2	1
64	Tuberculosis at Edendale Hospital in Pietermaritzburg, Kwazulu Natal, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2004 , 8, 1472-8	2.1	15

(2000-2003)

63	An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. <i>Contemporary Clinical Trials</i> , 2003 , 24, 481-500		28
62	A review of low-dose ritonavir in protease inhibitor combination therapy. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1585-92	11.6	132
61	Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. <i>Clinical Infectious Diseases</i> , 2002 , 35, 873-9	11.6	43
60	Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10. <i>Vaccine Journal</i> , 2002 , 9, 1212-21		9
59	Targeted HIV treatment to sex workers to promote HIV prevention. <i>Journal of the International Association of Providers of AIDS Care</i> , 2002 , 1, 51-2		2
58	Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. <i>Aids</i> , 2002 , 16, 1251-6	3.5	57
57	Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies. <i>Clinical Infectious Diseases</i> , 2002 , 34, 658-61	11.6	3
56	A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 149-58	6.1	20
55	Cloning, overexpression, purification, and immunobiology of an 85-kilodalton outer membrane protein from Haemophilus ducreyi. <i>Infection and Immunity</i> , 2001 , 69, 4438-46	3.7	35
54	Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. <i>Journal of Infectious Diseases</i> , 2001 , 183, 392-400	7	29
53	A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. <i>Sexually Transmitted Diseases</i> , 2001 , 28, 579-97	2.4	371
52	Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. <i>Journal of Infectious Diseases</i> , 2001 , 183, 546-54	7	50
51	Safe use of the CXCR4 inhibitor ALX40-4C in humans. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 475-86	1.6	111
50	Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. <i>HIV Clinical Trials</i> , 2001 , 2, 160-70		16
49	An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. <i>Aids</i> , 2001 , 15, 417-9	3.5	27
48	Flow cytometric measurement of telomere length. <i>Cytometry</i> , 2000 , 42, 159-64		34
47	Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 108-15	3.8	52
46	Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus. British Journal of Cancer, 2000, 82, 446-51	8.7	86

45	Reproductive factors are crucial in the aetiology of breast cancer - a reply. <i>British Journal of Cancer</i> , 2000 , 83, 134-134	8.7	78
44	Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 637-46	6.1	61
43	Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 559-67	1.6	88
42	Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999 , 21, 371		18
41	Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy. <i>Clinical Infectious Diseases</i> , 1999 , 29, 702-3	11.6	10
40	Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 1073-7	1.6	19
39	Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 168-79	3.8	62
38	Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. <i>Clinical and Experimental Immunology</i> , 1999 , 117, 84-91	6.2	27
37	Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. <i>Cell Death and Differentiation</i> , 1999 , 6, 420-32	12.7	88
36	Ritonavir and saquinavir combination therapy for the treatment of HIV infection. <i>Aids</i> , 1999 , 13, 213-24	3.5	149
35	Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 21, 371	3.1	72
34	Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. <i>Clinical and Experimental Immunology</i> , 1998 , 114, 78-86	6.2	29
33	Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. <i>Lancet, The</i> , 1998 , 351, 543-9	40	439
32	HIV resistance to antiviral drugs: public health implications. <i>Drug Resistance Updates</i> , 1998 , 1, 104-8	23.2	5
31	Amplicor HIV monitor, NASBA HIV-1 RNA QT and quantiplex HIV RNA version 2.0 viral load assays: a Canadian evaluation. <i>Journal of Clinical Virology</i> , 1998 , 11, 189-202	14.5	19
30	Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. <i>Journal of Infectious Diseases</i> , 1998 , 177, 898-904	7	110
29	Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 19, 124-9		54
28	Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. <i>Annals of Internal Medicine</i> , 1997 , 127, 289-93	8	121

[1990-1996]

27	Reduced Oral Absorption of Tuberculosis Drugs in HIV Infection. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 142-142	6.1	5
26	Evaluation of humoral and cell-mediated inducible immunity to Haemophilus ducreyi in an animal model of chancroid. <i>Infection and Immunity</i> , 1996 , 64, 1778-88	3.7	13
25	Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996 , 13, 27-32		6
24	Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. <i>Annals of Internal Medicine</i> , 1995 , 123, 584-7	8	6
23	Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 1995 , 21, 1008-11	11.6	12
22	Quantitative PCR for the measurement of circulating proviral load in HIV-infected individuals. <i>Clinical and Diagnostic Virology</i> , 1995 , 3, 95-104		3
21	Inducible immunity with a pilus preparation booster vaccination in an animal model of Haemophilus ducreyi infection and disease. <i>Infection and Immunity</i> , 1995 , 63, 2012-20	3.7	17
20	Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. <i>Journal of Infectious Diseases</i> , 1994 , 169, 1103-7	7	89
19	Rifabutin prophylaxis against Mycobacterium avium complex infection. <i>New England Journal of Medicine</i> , 1994 , 330, 436-7; author reply 438	59.2	5
18	Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 1993 , 36, 128-31	3.8	8
17	Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. <i>New England Journal of Medicine</i> , 1993 , 329, 828-33	59.2	389
16	The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 1992 , 33, 657-60	3.8	22
15	Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 464-70	6.1	9
14	Standardization of an enzyme immunoassay for human antibody to Haemophilus ducreyi. <i>Journal of Clinical Microbiology</i> , 1992 , 30, 2019-24	9.7	21
13	Condom use prevents genital ulcers in women working as prostitutes. Influence of human immunodeficiency virus infection. <i>Sexually Transmitted Diseases</i> , 1991 , 18, 188-91	2.4	23
12	Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. <i>Journal of Infectious Diseases</i> , 1991 , 163, 233-9	7	627
11	Heterosexual transmission of human immunodeficiency virus infection - Strategies for prevention. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1991 , 2, 30-6		1
10	Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. <i>Aids</i> , 1990 , 4, S105	3.5	20

9	Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli O157:H7. <i>American Journal of Medicine</i> , 1990 , 88, 177-9	2.4	39
8	Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. <i>Aids</i> , 1990 , 4 Suppl 1, S99-103	3.5	9
7	Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. <i>Scandinavian Journal of Infectious Diseases, Supplement</i> , 1990 , 69, 181-6		13
6	Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. <i>Antimicrobial Agents and Chemotherapy</i> , 1989 , 33, 612-4	5.9	56
5	Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. <i>Lancet, The</i> , 1989 , 2, 403-7	40	489
4	Comparison of Sheffield media with standard media for the isolation of Haemophilus ducreyi. <i>Sexually Transmitted Diseases</i> , 1989 , 16, 88-90	2.4	10
3	Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. <i>Lancet, The</i> , 1988 , 2, 887-90	40	137
2	Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. <i>New England Journal of Medicine</i> , 1988 , 319, 274-8	59.2	346
1	Heterosexual transmission of HIV. Aids, 1987, 1, 199-206	3.5	42